Silo pharma and partner receive regulatory approval to begin development of ketamine implant for fibromyalgia

Silo dosage and time-release formulation aim for potential first at-home ketamine therapeutic sarasota, fl, dec. 28, 2023 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or “the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its dosage and time-release ketamine-loaded implant, designated as sp-26, which is being developed as a potential at-home pain relief treatment for fibromyalgia and other chronic pain conditions. in collaboration with sever pharma solutions, silo's contract development and manufacturing partner, sp-26 is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
SILO Ratings Summary
SILO Quant Ranking